Calpains

Introduction

Calpains is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate proteins in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking amyloid-beta toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in Alzheimer’s disease and other neurodegenerative conditions (Bhatt et al., 2012). ^{1Marked calpastatin (CAST depletion in Alzheimer''s Disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression2008 · J Neurosci · DOI 10.1523/JNEUROSCI.2799-08.2008Open reference}

Calpain overactivation in AD operates through a devastating cascade: Aβ-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating CDK5, degrade PP2A (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. ^{2Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. *J Neurosci*. 2014;34(28):9222-9234. DOI2014 · DOI 10.1523/JNEUROSCI.4227-13.2014Open reference}

Structure and Isoforms

Calpain Family

The human genome encodes 15 calpain isoforms. The two ubiquitous “classical” calpains are most relevant to neurodegeneration: ^{3Neurotoxicity induces cleavage of p35 to p25 by calpain. *Nature*. 2000;405(6784):360-364. DOI2000 · DOI 10.1038/35012636Open reference}

| Isoform | Also Known As | Ca2+ Requirement | Brain Expression | Disease Relevance | ^{4The calpain system. *Physiol Rev*. 2003;83(3):731-801. DOI2003 · DOI 10.1152/physrev.00029.2002Open reference} |---------|---------------|-----------------|-----------------|-------------------| ^{5Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. *PLoS One*. 2009;4(1):e4201. DOI2009 · DOI 10.1371/journal.pone.0004201Open reference} | Calpain-1 | μ-calpain | Micromolar (~3-50 μM) | Neurons] (synapses, cell body) | Synaptic plasticity; protective at physiological levels | ^{6traumatic brain injury. *J Med Chem*. 2022;65(2):743-766. DOI2022 · DOI 10.1021/acs.jmedchem.1c01856Open reference} | Calpain-2 | m-calpain | Millimolar (~0.4-0.8 mM) in vitro; lower in vivo due to regulation | neurons, glia | Pathological; mediates excitotoxic damage | ^{7Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. *Nature*. 1999;402(6762):615-622. DOI1999 · DOI 10.1038/45159Open reference} | Calpain-5 | — | Unknown | Retina, brain | Retinal degeneration | ^{8PP2A by calpain and implications for Alzheimer's Disease. *Front Aging Neurosci*. 2015;7:209. DOI2015 · DOI 10.3389/fnagi.2015.00209Open reference} | Calpain-10 | — | Unknown | Ubiquitous | Linked to type 2 diabetes susceptibility | ^{9Wang KKW. Calpain and caspase: can you tell the difference? *Trends Neurosci*. 2000;23(1):20-26. DOI:10.1016/S0166-2236(99)(2000 · Trends Neurosci · DOI 10.1016/S0166-2236(99Open reference}

Molecular Architecture

Classical calpains (calpain-1 and -2) are heterodimers: ^{10Bhatt AB. Calpain-mediated proteolysis of the spectrin cytoskeleton in a mouse model of Alzheimer's Disease. *J Neurosci Res*. 2013;91(7):884-893. DOI2013 · DOI 10.1002/jnr.23219Open reference}

Large (catalytic) subunit (~80 kDa; CAPN1 or CAPN2):

• Domain I: N-terminal anchor helix

• Domain II (protease core): Cysteine protease catalytic domain (papain-like fold); divided into IIa and IIb subdomains containing the catalytic triad (Cys105, His262, Asn286)

• Domain III: C2-like domain; binds phospholipids and calcium

• Domain IV: Penta-EF-hand domain; binds calcium; mediates heterodimerization

Small (regulatory) subunit (~28 kDa; CAPNS1):

• Domain V: Glycine-rich hydrophobic region

• Domain VI: Penta-EF-hand domain; dimerizes with domain IV

Activation Mechanism

1. Calcium binds to EF-hand domains in both subunits

2. Conformational change brings IIa and IIb subdomains together, assembling the active site

3. Autolysis of the N-terminal anchor removes the small subunit

4. Active calpain performs limited proteolysis of substrates (cuts at specific sites, not complete degradation)

Calpastatin: Endogenous Calpain Inhibitor

Calpastatin (encoded by CAST) is the only known endogenous specific inhibitor of classical calpains:

• Contains four inhibitory domains, each capable of inhibiting one calpain molecule

• Binds to calcium-activated calpain with extremely high affinity

• Calpastatin itself is a calpain substrate — creating a destructive feedback loop when calpain is overactivated

• Critical AD finding: Calpastatin is markedly depleted (~50-75%) in AD brain (Bhatt et al., 2008), removing the brake on calpain activity

• Calpastatin overexpression in tau] P301L mice prevents tauopathy, tau] fragmentation, and neurodegeneration, and restores normal lifespan (Bhatt et al., 2014)

Role in Alzheimer’s Disease

Calcium-Calpain Cascade

In AD, multiple sources of pathological calcium elevation drive calpain overactivation:

1. Aβ oligomer-formed membrane pores: Direct calcium influx into neurons

2. NMDA receptor] receptor] overactivation: Excitotoxic calcium entry

3. Ryanodine receptor leak: Chronic ER calcium release (especially with presenilin mutations)

4. Mitochondrial calcium buffering failure: Impaired sequestration of excess calcium

5. Reduced calpastatin: Loss of endogenous inhibition amplifies the cascade

Calpain-CDK5/p25 Pathway

One of the most pathologically significant calpain substrates is p35, the regulatory activator of CDK5:

1. Calpain cleaves p35 (306 aa) to generate p25 (208 aa) — removing the membrane-targeting myristoylation signal

2. p25 constitutively activates CDK5 and causes its mislocalization from the membrane to the cytoplasm and nucleus

3. CDK5/p25 hyperphosphorylates tau] at multiple AD-relevant sites (Ser202, Thr205, Ser235, Ser404)

4. CDK5/p25 also phosphorylates APP, enhancing BACE1, reducing its activity

• Calpain also cleaves I2PP2A/SET, generating fragments that inhibit remaining PP2A

• Net effect: ~50% reduction in PP2A activity in AD brain

• Combined with CDK5/p25 activation, this creates a kinase-phosphatase imbalance maximally favoring tau hyperphosphorylation]

Calpain-Mediated Tau Truncation

Calpains directly cleave tau](/proteins/tau at multiple sites:

• Generate truncated tau fragments (e.g., tau 17 kDa fragment) that are highly aggregation-prone

• Truncated tau acts as a seed for further tau oligomerization and tangle formation

• Calpain-generated tau fragments are found in NFTs in AD brain

• These fragments are more neurotoxic than full-length hyperphosphorylated tau

BACE1 Upregulation

• Calpain activation increases BACE1 expression and stability in neurons

• Mechanism involves calpain-mediated cleavage of the BACE1 translational repressor GGA3

• Increased BACE1 enhances Aβ production, further driving calcium influx — a feed-forward loop

Synaptic Destruction

Calpain-mediated proteolysis of synaptic proteins drives cognitive decline:

Substrate	Function	Consequence of Cleavage
αII-spectrin (fodrin)	Membrane cytoskeleton scaffold	Loss of dendritic spine structure; spectrin breakdown products (SBDPs) are biomarkers
PSD-95	Postsynaptic scaffold	Disrupted receptor clustering and synaptic transmission
Homer1	Postsynaptic scaffold	Impaired metabotropic glutamate receptor signaling
NMDA receptor] receptor subunits	Excitatory receptor	Altered receptor function and trafficking
Dynamin-1	Synaptic vesicle endocytosis	Impaired synaptic vesicle recycling
GAP-43	Growth cone/synaptic plasticity	Reduced synaptic remodeling

Apoptosis and Necrosis

Calpain activation contributes to neuronal death through multiple mechanisms:

• Cleavage of pro-caspase-3 → activation of caspase cascade → apoptosis

• Cleavage of Bid → truncated Bid (tBid) → mitochondrial cytochrome c release

• Degradation of Bcl-2 and Bcl-xL → loss of anti-apoptotic protection

• Cleavage of AIF (apoptosis-inducing factor) → caspase-independent cell death

• Calpain-caspase crosstalk: caspases also cleave calpastatin, further amplifying calpain activity

Calpain in Other Neurodegenerative Diseases

Parkinson’s Disease

• α-Synuclein is a calpain substrate; truncated fragments promote aggregation

• Calpain-mediated cleavage of Parkin reduces its E3 ligase activity

• Dopaminergic neurons in the substantia nigra are particularly vulnerable to calcium-calpain damage

ALS

• TDP-43 is cleaved by calpains to generate aggregation-prone 25 kDa and 35 kDa fragments found in ALS inclusions

• Motor neurons express high calpain-1 levels, increasing vulnerability

Huntington’s Disease

• Mutant huntingtin is cleaved by calpains, generating toxic N-terminal fragments

• Calpain-resistant huntingtin mutants show reduced toxicity in models

Traumatic Brain Injury

• Acute calpain activation is a hallmark of TBI

• αII-spectrin breakdown products (SBDPs) in CSF and blood are established TBI biomarkers

• Chronic calpain activation after TBI may contribute to post-traumatic neurodegeneration (CTE)

Therapeutic Targeting

Calpain Inhibitors

Compound	Mechanism	Status	Key Findings
SNJ-1945 (BLD-2660)	Reversible, brain-penetrant calpain inhibitor	Phase 1	Reduces tau pathology] in AD mice; good oral bioavailability
PD150606	Non-competitive calpain-1/2 inhibitor	Preclinical	Selectively inhibits calpains vs. cathepsins
MDL-28170	Cell-permeable calpain inhibitor	Preclinical	Neuroprotective in excitotoxicity and ischemia models
E-64d	Broad cysteine protease inhibitor	Preclinical	Reduces Aβ pathology; limited selectivity

Calpastatin-Based Strategies

• Calpastatin gene therapy: AAV-mediated CAST overexpression prevents tauopathy in mice and restores lifespan

• Calpastatin-mimetic peptides: Smaller peptides based on the inhibitory domain of calpastatin

• Calpastatin stabilization: Preventing calpain-mediated degradation of calpastatin

Upstream Calcium-Targeting Approaches

Rather than directly inhibiting calpains, targeting upstream calcium dysregulation:

• NMDA receptor receptor] antagonists (memantine — FDA-approved for AD)

• Ryanodine receptor stabilizers (Rycal compounds)

• Voltage-gated calcium channel blockers

• Restoring ER calcium homeostasis

Biomarkers

Spectrin Breakdown Products (SBDPs)

• Calpain-generated αII-spectrin fragments (SBDP150, SBDP145) are detectable in CSF and blood

• Established biomarkers in TBI; under investigation for AD

• Distinguish calpain-mediated (SBDP145) from caspase-mediated (SBDP120) cleavage patterns

See Also

• BACE1 ([Beta-Secretase

External Links

• PubMed — Biomedical literature database

• Allen Brain Atlas — Brain gene expression data

Background

The study of Calpains has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: Calpains expression search

• Allen Mouse Brain Atlas: Calpains search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Calpains developmental expression